Are there any new pass-through drugs for the upcoming quarter?
The Centers for Medicare & Medicaid Services (CMS) have granted outpatient prospective payment system (OPPS) pass-through status, effective July 1, 2018 the following drugs and biological:
|C9030||Injection, copanlisib, 1 mg|
|C9031||Lutetium Lu 177, dotatate, therapeutic, 1 mCi|
|C9032||Injection, voretigene neparvovec-rzyl, 1 billion vector genome|
|Q9991||Injection, buprenorphine extendedrelease (Sublocade), less than or equal to 100 mg|
|Q9992||Injection, buprenorphine extendedrelease (Sublocade), greater than 100 mg|
|Q9995||Injection, emicizumab-kxwh, 0.5 mg|